Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuya Hosaka

Showing results (121-130 of 306) with videos related to

Pageof 31
Sort By:
The American Journal of Medicine|October 6, 2010
Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patientsYusuke Kawamura, Yasuji Arase, Kenji Ikeda, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 31, 2018
Recurrence rates of pruritus after the stop of nalfurafine hydrochloride in chronic liver disease: Preliminary prospective confirmatory trialNorio Akuta, Hiromitsu Kumada, Shunichiro Fujiyama, et al.
Oncology|June 29, 2011
Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinomaNorihiro Imai, Kenji Ikeda, Yuya Seko, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 23, 2021
Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long-term other nucleotide analog treatment in patients with chronic hepatitis BTetsuya Hosaka, Fumitaka Suzuki, Masahiro Kobayashi, et al.
Intervirology|January 8, 2009
Lipiodol and dye at the site of ablation decreases during RFAMiharu Hirakawa, Kenji Ikeda, Yusuke Kawamura, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 5, 2008
Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicinYusuke Kawamura, Kenji Ikeda, Miharu Hirakawa, et al.
Journal of Medical Virology|June 14, 2018
Circulating microRNA-122 levels are important predictor of hepatitis B virus surface antigen seroclearanceNorio Akuta, Fumitaka Suzuki, Mariko Kobayashi, et al.
Journal of Hepatology|April 19, 2006
Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohortsKenji Ikeda, Yasuji Arase, Satoshi Saitoh, et al.
Hepatology (Baltimore, Md.)|December 6, 2012
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infectionTetsuya Hosaka, Fumitaka Suzuki, Masahiro Kobayashi, et al.
Journal of Medical Virology|October 25, 2013
Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis CYasuji Arase, Mariko Kobayashi, Yusuke Kawamura, et al.
Pageof 31

Showing results (121-130 of 306) with videos related to

Sort By:
Pageof 31
The American Journal of Medicine|October 6, 2010
Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patientsYusuke Kawamura, Yasuji Arase, Kenji Ikeda, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 31, 2018
Recurrence rates of pruritus after the stop of nalfurafine hydrochloride in chronic liver disease: Preliminary prospective confirmatory trialNorio Akuta, Hiromitsu Kumada, Shunichiro Fujiyama, et al.
Oncology|June 29, 2011
Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinomaNorihiro Imai, Kenji Ikeda, Yuya Seko, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 23, 2021
Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long-term other nucleotide analog treatment in patients with chronic hepatitis BTetsuya Hosaka, Fumitaka Suzuki, Masahiro Kobayashi, et al.
Intervirology|January 8, 2009
Lipiodol and dye at the site of ablation decreases during RFAMiharu Hirakawa, Kenji Ikeda, Yusuke Kawamura, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 5, 2008
Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicinYusuke Kawamura, Kenji Ikeda, Miharu Hirakawa, et al.
Journal of Medical Virology|June 14, 2018
Circulating microRNA-122 levels are important predictor of hepatitis B virus surface antigen seroclearanceNorio Akuta, Fumitaka Suzuki, Mariko Kobayashi, et al.
Journal of Hepatology|April 19, 2006
Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohortsKenji Ikeda, Yasuji Arase, Satoshi Saitoh, et al.
Hepatology (Baltimore, Md.)|December 6, 2012
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infectionTetsuya Hosaka, Fumitaka Suzuki, Masahiro Kobayashi, et al.
Journal of Medical Virology|October 25, 2013
Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis CYasuji Arase, Mariko Kobayashi, Yusuke Kawamura, et al.
Pageof 31